



## **Enzymicals AG Expands Off-the-Shelf Enzyme Collection: Unlocking Boundless Biotech Possibilities**

Greifswald (Germany), June 19<sup>th</sup>, 2023 – Enzymicals AG, a German enterprise focusing on industrial biocatalysis, announces a significant expansion of its enzyme collection through in-house activities and third-party collaborations. Leveraging one of the world's largest collections of naturally occurring and synthetically useful biocatalysts, the company now offers comprehensive screening services to identify excellent enzymes with a high probability of success. With its chemical expertise, Enzymicals can directly translate screening hits into optimised processes and kilogram-scale syntheses through tailor-made development programs. This unique opportunity in the industry includes a flexible business model that allows for subsequent catalyst supply or even outsourcing of enzyme production to the customer or a preferred contract manufacturing organization.

As a leading biotech company at the forefront of innovation, Enzymicals is committed to empowering researchers and scientists involved in industrial biocatalysis with cutting-edge tools to accelerate their developments through contract research. The expanded collection boasts an unparalleled diversity of screening enzymes meticulously curated to meet the evolving demands of the biotech industry. By combining expertise and resources, the collection includes more than 3,500 enzymes in over 50 enzyme classes ready for application. From reductases to hydrolases, transferases to ligases, and many other synthetically useful enzyme classes, Enzymicals offers a comprehensive selection tailored to specific research needs. With this significant enhancement, Enzymicals continues its commitment to providing innovative solutions and empowering experts in accelerating breakthroughs in cell-free manufacturing. This represents a new example of how Enzymicals works with other SMEs for mutual benefit and success to push the boundaries of biotech innovation even further.

Dr. Erik de Vries, CEO of Enzymicals AG, states: "By providing researchers with access to these advanced tools, we aim to facilitate groundbreaking discoveries and catalyse innovation across various fields of biotechnology. Our commitment to scientific excellence and customer satisfaction remains unwavering, and we invite you to embark with us on a journey of limitless possibilities in biotechnology."



Recognizing the uniqueness of each project, Enzymicals adopts a personalised approach to cater to specific requirements from the outset. Identifying a suitable catalyst for a specific reaction involves a combination of experimental and theoretical approaches. A team of experienced experts is readily available to provide guidance, recommend the most suitable screening panel, and assist in optimising experimental conditions closely aligned with the envisioned manufacturing process. With its focus on the application of biocatalysts in chemical synthesis and the establishment and scaling of the entire production process, Enzymicals can conduct reliable process evaluations. The company's equal attention to biological and chemical aspects, along with its related expertise, enables efficient catalyst manufacturing and production of target molecules. This comprehensive approach allows for early-stage assessments of the economic viability of a synthesis route and the identification and overcoming of potential limitations.

With this expanded collection of biocatalysts, Enzymicals reaffirms its position as a leading provider of innovative biotechnology solutions for the pharma and fine chemicals industries.

For more information contact Dr. Rainer Wardenga at [rainer.wardenga@enzymicals.com](mailto:rainer.wardenga@enzymicals.com)

>50 ENZYME PANELS >3.500 BIOCATALYSTS



READY FOR YOUR DEVELOPMENT PROGRAM



## **About Enzymicals AG**

Operating almost 15 years in the industry, Enzymicals is your experienced partner for industrial biocatalysis from initial catalyst-lead finding to process optimisation and scale-up from gram to ton-scale. With technologies, products and offerings for the industrial implementation of cell-free manufacturing (also known as biocatalysis), Enzymicals supports the global industry to enable the change to biologically-inspired production concepts. Besides biocatalysis, our services include enzymology, cloning and expression services in multiple hosts (*E. coli*, *Bacillus*, *Pichia*), and strain and fermentation development for (therapeutic/diagnostic) protein manufacture.

Core working principles are high quality R&D, professionalism and customer satisfaction. By this, our company adds value with tailor-made enzymes, customized chemicals and individual process solutions and enables greener and safer manufacturing procedures.